Merck & Company Inc (MRK)vsModerna Inc (MRNA)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
MRNA
Moderna Inc
$47.44
-8.04%
HEALTHCARE · Cap: $19.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2856% more annual revenue ($65.77B vs $2.23B). MRK leads profitability with a 13.6% profit margin vs -143.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
MRNA
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+71.2%
Fair Value
$140.45
Current Price
$47.44
$93.01 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 260.2% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Weak financial health signals
ROE of -43.1% — below average capital efficiency
Earnings declined 85.1%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : MRNA
The strongest argument for MRNA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 260.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while MRNA is a hypergrowth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.03 — expect wider price swings.
MRNA is growing revenue faster at 260.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 34/100). MRNA offers better value entry with a 71.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?